乐
乐观
乐观 · 25%MIST
$2.13
情景价格
$0.693
-0.072 (-10.36%)收盘时
Loading chart…
- 最高
- 0.785
- 开盘
- 0.761
- 成交量加权均价
- 0.72
- 成交量
- 1.19M
- 市值
- 68.71M
- 最低
- 0.675
- 成交额
- 856.11K
- 企业价值/息税折旧摊销前利润（TTM）
- -0.08
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
AI 分析 of Milestone Pharmaceuticals Inc (MIST)
买入Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
估值指标
Milestone Pharmaceuticals Inc（MIST）当前预期市盈率为 0.00，5 年平均预期市盈率为 -2.72。
Alphio AI 对 MIST 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
5.011-04NewsfilterMilestone Pharmaceuticals Grants 33,000 Stock Options to New Employee
9.009-27NASDAQ.COMMilestone Pharmaceuticals Initiates Phase 3 Trial for Etripamil
9.009-03NASDAQ.COMMilestone Pharmaceuticals Secures Approval for Etripamil in China
- 8.509-03Newsfilter
Everest Medicines to Lead Etripamil Commercialization in Greater China
9.008-21NASDAQ.COMMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial for Etripamil in AFib-RVR
MIST 常见问题 —— 由 Alphio AI 解答
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Milestone Pharmaceuticals Inc is a good buy right now due to its recent approval for etripamil in China, which triggered a $2 million milestone payment and opens up a significant market opportunity. The current price is $0.7268, and analysts project a price target of $3, suggesting a potential upside of approximately 313%. Additionally, the stock has shown a 5-day change of +12.79%, indicating positive momentum. However, the main risk is the company's substantial net losses, with a net income of -$28,614,000 in Q2 2026.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。